Dendreon lowers expectations, touts DTC effort

Share this article:

Biotech Dendreon posted narrower second-quarter losses, logging a $69-million revenue shortfall for the quarter ended June 30, compared to $96 million for the same period last year. The net loss mirrored a dip in overall sales, which were $73 million for the quarter, compared to $80 million for the same period last year. As for a possible turnaround, management said the firm will not hit its year-over-year sales target.

Yet CEO John Johnson remains optimistic, because of 42 new accounts added in the quarter and because of increased consumer interest since initiation of a television DTC campaign March 7 for prostate cancer drug Provenge. The company said the TV ad serves a dual purpose: in addition to triggering calls into its phone centers, the spot also has unique dial-in numbers, helping the firm identify which channels are bringing in traffic.

 

The company could not share the patient conversion rates from caller to user, but management told investors during the August 8 earnings call that consumers need to see the ad about seven times before they are ready to dial in.

Johnson said the company's marketing efforts for Provenge have run into a few hurdles, with a key one being patients' lack of familiarity with immunotherapy. Marketing and awareness efforts are designed to explain the approach.

Dendreon is also looking to get a foothold in the pre-chemo space, so it can be used earlier in the treatment roster, and is considering sequencing studies with other prostate therapies, such as with the oral Astellas/Medivation drug Xtandi (enzalutemide) and with Janssen pill Zytiga (abiraterone acetate).

The company's sales efforts have focused on large accounts like community oncology centers, which provided about 38% of the business during the quarter, management said. Zytiga is posing stiff competition in smaller, low-volume accounts.
Share this article:
You must be a registered member of MMM to post a comment.

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...